DS-3939
Phase 1/2- Indications
- Advanced Malignant Solid Neoplasm
Company intelligence / Profile preview
Glycotope
Berlin, Germanyglycotope.com ↗
- Ownership
- Private
- Employees
- ~80
- Development stage
- Phase 3
01
Overview
Proprietary antibody platform targeting tumor-associated carbohydrates; two Phase III-ready assets among six+ total programs; >2000 patients dosed overall. Service division spun off as FyoniBio in Feb.2022 so focus is now solely on drug discovery/development using GEX tech.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesBispecificsADCsCellular therapiesFusion proteins
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Licensing partners' unnamedcollaboration w/FyoniBio post-spinout
Beyond the preview
Go deeper on Glycotope.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycotope.